Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

109 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A multicenter real-world study of bevacizumab in heavily pretreated malignant gliomas: clinical benefit is a plausible end point?
Villani V, Fabi A, Tanzilli A, Pasqualetti F, Lombardi G, Vidiri A, Gonnelli A, Molinari A, Cantarella M, Bellu L, Terrenato I, Carosi M, Maschio M, Telera SM, Carapella CM, Cognetti F, Paiar F, Zagonel V, Pace A. Villani V, et al. Among authors: carosi m. Future Oncol. 2019 May;15(15):1717-1727. doi: 10.2217/fon-2018-0826. Epub 2019 Apr 12. Future Oncol. 2019. PMID: 30977687
Phase II study of fixed dose rate gemcitabine as radiosensitizer for newly diagnosed glioblastoma multiforme.
Metro G, Fabi A, Mirri MA, Vidiri A, Pace A, Carosi M, Russillo M, Maschio M, Giannarelli D, Pellegrini D, Pompili A, Cognetti F, Carapella CM. Metro G, et al. Among authors: carosi m. Cancer Chemother Pharmacol. 2010 Jan;65(2):391-7. doi: 10.1007/s00280-009-1155-x. Epub 2009 Oct 22. Cancer Chemother Pharmacol. 2010. PMID: 19847425 Clinical Trial.
Low-dose fotemustine for recurrent malignant glioma: a multicenter phase II study.
Fabi A, Metro G, Vidiri A, Lanzetta G, Carosi M, Telera S, Maschio M, Russillo M, Sperduti I, Carapella CM, Cognetti F, Pace A. Fabi A, et al. Among authors: carosi m. J Neurooncol. 2010 Nov;100(2):209-15. doi: 10.1007/s11060-010-0163-3. Epub 2010 Mar 30. J Neurooncol. 2010. PMID: 20352471 Clinical Trial.
Comparative evaluation of nm23 and p16 expression as biomarkers of high-risk human papillomavirus infection and cervical intraepithelial neoplasia 2(+) lesions of the uterine cervix.
Benevolo M, Terrenato I, Mottolese M, Marandino F, Muti P, Carosi M, Rollo F, Ronchetti L, Mariani L, Vocaturo G, Vocaturo A. Benevolo M, et al. Among authors: carosi m. Histopathology. 2010 Oct;57(4):580-6. doi: 10.1111/j.1365-2559.2010.03674.x. Histopathology. 2010. PMID: 20955383
Diagnostic and prognostic validity of the human papillomavirus E6/E7 mRNA test in cervical cytological samples of HC2-positive patients.
Benevolo M, Terrenato I, Mottolese M, Marandino F, Carosi M, Rollo F, Ronchetti L, Muti P, Mariani L, Sindico S, Vocaturo G, Vocaturo A. Benevolo M, et al. Among authors: carosi m. Cancer Causes Control. 2011 Jun;22(6):869-75. doi: 10.1007/s10552-011-9757-0. Epub 2011 Mar 19. Cancer Causes Control. 2011. PMID: 21424209
109 results